ARTVArtiva Biotherapeutics Inc
$6.85
$0.83
(10.81%)
Closed $6.85
$0.45
(6.57%)
After Hours
Reported EarningsMay 8
Mkt Cap$169.31M
Vol361,057.00
Fundamentals
Mkt Cap
$169.31M
Volume
-
52W High
$14.53
52W Low
$1.47
PE Ratio
-1.93
Avg. Volume
684,528.01
EPS (Annual)
-$3.43
Rev/Employee
$0.00
Earnings
May 08
40
Bearish Sentiment
How do you feel about ARTV?
The $13 Million Company Teaching the Immune System to Hunt Cancer
The $13 Million Company Teaching the Immune System to Hunt Cancer The $13 Million Company Teaching the Immune System to Hunt Cancer PR Newswire NEW YORK, May 29, 2026 Issued on behalf of GT Biopharma, Inc. (NASDAQ: GTBP)Three drugs in human trials. A platform licensed from one of the world's top...
PR Newswire
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth...
PR Newswire
ARTV Stock Pares Majority Of Pre-Market Gains – $300M Offering Overshadows Strong Data For Rheumatoid Arthritis Therapy
Artiva announced a $300 million public offering to support the development of its autoimmune disease therapies, but at a 9% discount per share compared to Thursday’s closing price.
Artiva Biotherapeutics Prices $300 Mln Stock, Pre-Funded Warrants Offering; Shares Rise
(RTTNews) - Artiva Biotherapeutics, Inc. (ARTV), a clinical-stage biotechnology company, on Friday announced the pricing of an underwritten offering of stock and pre-funded warrants...
Nasdaq News: Markets
Artiva Biotherapeutics (NASDAQ:ARTV) Earns "Buy" Rating from Needham & Company LLC
Needham & Company LLC reissued a "buy" rating and issued a $18.00 price target on shares of Artiva Biotherapeutics in a research note on Monday...
MarketBeat
Artiva Biotherapeutics (NASDAQ:ARTV) Cut to "Sell" at Wall Street Zen
Wall Street Zen downgraded Artiva Biotherapeutics from a "hold" rating to a "sell" rating in a research note on Tuesday...
MarketBeat
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Average Recommendation of "Moderate Buy" from Analysts
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the five analysts that are covering the stock, Marketbeat.com reports. One...
MarketBeat
Artiva Biotherapeutics (NASDAQ:ARTV) Raised to "Hold" at Wall Street Zen
Wall Street Zen upgraded shares of Artiva Biotherapeutics from a "sell" rating to a "hold" rating in a research report on Monday...
MarketBeat
Artiva Biotherapeutics Spotlights RA as Lead NK Cell Program, Eyes H1 Efficacy Data Catalyst at Needham
Artiva Biotherapeutics (NASDAQ:ARTV) is prioritizing rheumatoid arthritis (RA) as the lead indication for its non-genetically modified natural killer (NK) cell therapy platform, executives said...
MarketBeat
Artiva Biotherapeutics (NASDAQ:ARTV) Stock Rating Lowered by Wall Street Zen
Wall Street Zen lowered Artiva Biotherapeutics from a "hold" rating to a "sell" rating in a research note on Sunday...
MarketBeat
<
1
2
...
>
Advertisement|Remove ads.
Latest ARTV News
ViewThe $13 Million Company Teaching the Immune System to Hunt Cancer
PR Newswire
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
PR Newswire
ARTV Stock Pares Majority Of Pre-Market Gains – $300M Offering Overshadows Strong Data For Rheumatoid Arthritis Therapy
Stocktwits
Advertisement|Remove ads.